Boston Scientific continues acquisition streak, eyes Newton cancer treatment provider
Photo | Courtesy Boston Scientific
Boston Scientific headquarters in Marlborough
Boston Scientific is expanding its presence in cancer treatment as the Marlborough-based medical device manufacturer intends to acquire Intera Oncology, a Newton-based medical device company focused on interventional oncology therapy.
As part of the deal, Boston Scientific will acquire the Intera 3000 Hepatic Artery Infusion Pump, an implantable device used in hepatic artery infusion therapy, a treatment in which chemotherapy drugs are delivered directly to the liver through an implanted pump. The Intera 3000 treats tumors primarily caused by metastatic colorectal cancer and is the only constant flow implantable pump for HAI therapy approved by the U.S. Food and Drug Administration, according to a Monday press release from Boston Scientific.
[What does 2025 hold for your business and the Central Mass. economy? Take WBJ’s Economic Forecast survey.]
Boston Scientific anticipates completing the acquisition in the first half of 2025 with the transaction subject to closing conditions. The manufacturer is not disclosing the financial terms of the deal, according to an email sent to WBJ.
"Liver cancer is a leading cause of cancer-related death, and we are committed to providing meaningful solutions to safely and effectively treat various forms of this disease with minimal systemic side effects and improved outcomes for patients," Peter Pattison, Boston Scientific president, interventional oncology and embolization, said in the release.
Boston Scientific reports approximately 1.4 million people in the U.S. have primary colorectal cancer, with more than 150,000 new cases diagnosed annually. Randomized controlled trials of HAI therapy have shown the treatment significantly improves tumor response, time to progression, and overall survival compared to systemic chemotherapy.
"Interest in HAI therapy has grown in the oncology community given improved techniques, positive clinical results and ongoing trials. We believe this acquisition will enable us to provide a more comprehensive set of solutions to physicians and their patients to treat both primary and metastatic forms of liver cancer," said Pattison.
Monday’s announcement continues a busy month of acquisitions for Boston Scientific. On Nov. 4, the manufacturer entered into a definitive agreement to acquire Cortex, a California medical technology company working to advance the treatment of atrial fibrillation, and on Nov. 15, it finalized its $3.7B purchase of Axonics, Inc., a publicly traded California-based medical technology firm specializing in devices used to treat urinary and bowel dysfunction.
Mica Kanner-Mascolo is a staff writer at Worcester Business Journal, who primarily covers the healthcare and diversity, equity, and inclusion industries.
WBJ Web Partners
Most Recent
Most Recent
0 Comments